August 17, 2020 article Open access Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma Cancers DOI: 10.3390/cancers12082311 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 5 stored of 89 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective 2024 Lung Cancer article Medicine Lung Cancer Treatments and Mutations Open access 18 citations EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023 2023 European Journal of Cancer article Medicine Cutaneous lymphoproliferative disorders research Open access 189 citations Kutane T-Zell-Lymphome: Low-dose Gemcitabin in der Therapie fortgeschrittener CTCL 2022 Kompass Dermatologie article Medicine Cutaneous lymphoproliferative disorders research 0 citations Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC 2021 Blood article Medicine Cutaneous lymphoproliferative disorders research Open access 182 citations Cutaneous T cell lymphoma 2021 Nature Reviews Disease Primers review Medicine Cutaneous lymphoproliferative disorders research 182 citations 5 results References 0